Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

Barth, Jessica; Abou-El-Ardat, Khalil; Dalic, Denis; Kurrle, Nina; Maier, Anna-Maria; Mohr, Sebastian; Schütte, Judith; Vaßen, Lothar; Greve, Gabriele; Schulz-Fincke, Johannes; Schmitt, Martin; Tošić, Milica; Metzger, Eric; Bug, Gesine; Khandanpour, Cyrus; Wagner, Sebastian; Lübbert, Michael; Jung, Manfred; Schüle, Roland; Berg, Tobias

doi:10.1038/s41375-019-0415-y

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lysine-specific histone demethylase 1 (LSD1) LSD1 inhibitors are widely applied in myeloid hematological malignancies as they promote the differentiation of myeloid cells via regulation of myeloid transcription factors GFI1 and PU.1. 497,498 Regarding anti-tumor immunity, LSD1 undermines T cell-mediated cytotoxicity via promoting terminal differentiation of T cells 499,500 (Fig. 4).…”

Section: The Mammalian Bromodomain and Extra-terminal Family Proteins...mentioning

confidence: 99%

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin,

Li,

Zhang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of novel immunoregulatory targets and mechanisms are being revealed, with relevant therapies promising to improve clinical immunotherapy in the foreseeable future. Therefore, comprehending the larger picture is important. In this review, we analyze and summarize the current landscape of preclinical and translational mechanistic research, drug development, and clinical trials that brought about next-generation pharmacological immunoregulatory anti-cancer agents and drug candidates beyond classical immune checkpoint inhibitors. Along with further clarification of cancer immunobiology and advances in antibody engineering, agents targeting additional inhibitory immune checkpoints, including LAG-3, TIM-3, TIGIT, CD47, and B7 family members are becoming an important part of cancer immunotherapy research and discovery, as are structurally and functionally optimized novel anti-PD-(L)1 and anti-CTLA-4 agents and agonists of co-stimulatory molecules of T cells. Exemplified by bispecific T cell engagers, newly emerging bi-specific and multi-specific antibodies targeting immunoregulatory molecules can provide considerable clinical benefits. Next-generation agents also include immune epigenetic drugs and cytokine-based therapeutics. Cell therapies, cancer vaccines, and oncolytic viruses are not covered in this review. This comprehensive review might aid in further development and the fastest possible clinical adoption of effective immuno-oncology modalities for the benefit of patients.

show abstract

Section: The Mammalian Bromodomain and Extra-terminal Family Proteins...mentioning

confidence: 99%

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin,

Li,

Zhang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

Cited by 1 publication

References 0 publications

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Contact Info

Product

Resources

About